Trades of Eli Lilly shares were made on Trump’s behalf as drugmaker benefitted from his policies
المصدر: The Guardian World | Source: The Guardian WorldFilings reveal $220m to $750m in trades on US president’s behalf in first quarter of 2026, including securities linked to largest US companies
Hundreds of thousands of dollars was invested in Eli Lilly on Donald Trump’s behalf earlier this year, according to financial disclosures, as the US drugmaker benefited from his administration’s bid to expand access to blockbuster obesity treatments.
Ethics filings revealed several thousand trades on the US president’s behalf tied to stocks and bonds in the first quarter of 2026, with a cumulative value of between $220m and around $750m.
Continue reading...
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة The Guardian World. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by The Guardian World. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
